Media

Select from the drop-down menu below to read the most up-to-date news about pelareorep.

October 13, 2017 | Publication
A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.
Bernstein, et al, Breast Cancer Research and Treatment, 2017
September 1, 2017 | Poster
Pooled data analysis of the safety and tolerability of intravenous Pelareorep in combination with chemotherapy in 500 + cancer patients
Gutierrez et al, ESMO, 2017
September 1, 2017 | Poster
Mechanism of Pelareorep (Pel)-mediated cell death in a Phase I study in combination with irinotecan/ fluorouracil/ leucovorin/ bevacizumab (FOLFIRI/B) in patients with KRAS mutant metastatic colorectal cancer (mCRC)
Goel et al, ESMO, 2017
April 1, 2017 | Poster
A randomized (RCT) phase II study of oncolytic reovirus (pelareorep) plus standard weekly paclitaxel (P) as therapy for metastatic breast cancer (mBC)
Bernstein et al, AACR, 2017
May 3, 2016 | Publication
Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (REOLYSIN®) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma
Noonan, Molecular Therapy vol. 24 no. 6 jun. 2016 1151
January 1, 2016 | Publication
Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses
Rajani et al, Molecular Therapy, 2016. 24(1): p. 166-74
January 1, 2016 | Publication
Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer
Samson, BMJ Hepatology, 2016
December 28, 2015 | Publication
Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors
Villalona-Calero et al., Cancer, 2016. 122(6): p. 875-83
July 10, 2015 | Publication
The combination of intravenous REOLYSIN® and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer
Mahalingam et al, BMC Cancer (2015) 15:513
July 1, 2015 | Poster
Oncolytic Virus Therapy in Pancreatic Cancer: Clinical Efficacy and Pharmacodynamic Analysis of REOLYSIN® in Combination with Gemcitabine in Patients with Advanced Pancreatic Adenocarcinoma
Mahalingam et al, EMSO, 2015
December 3, 2014 | Publication
Controlled infection with a therapeutic virus defines the activation kinetics of human natural killer cells in vivo
El-Sherbiny et al, The Journal of Translational Immunology, 2015. 180(1): p. 98-107
December 1, 2014 | Poster
Combination therapy with reovirus and immunomodulatory drugs induces direct oncolytic and immune-mediated killing of multiple myeloma cells and overcomes stromal-mediated microenvironmental protection
Parrish et al, ASH, 2014
May 1, 2014 | Poster
Combination therapy with reovirus and PD-1 blockade effectively establishes tumor control via innate and adaptive immune responses
Rajani et al, 2014
April 1, 2014 | Poster
PDL-1 blockade and Sunitinib enhance the efficiency of oncolytic viral therapy
Mostafa et al, AACR, 2014
July 18, 2013 | Publication
REOLYSIN® is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer
Cell Death & Disease, 2013. 4: p. e728

Contact Us

For questions regarding our science, partnership opportunities, or other inquiries, we encourage you to reach out.

Get in touch